肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2008年
4期
268-271
,共4页
叶欣%葛忠民%费兴波%吴珂%王双%程园园%陈祥明%魏林%张新丽%田瑞华
葉訢%葛忠民%費興波%吳珂%王雙%程園園%陳祥明%魏林%張新麗%田瑞華
협흔%갈충민%비흥파%오가%왕쌍%정완완%진상명%위림%장신려%전서화
肝肿瘤%超声%高强聚焦%结肠%化学栓塞%治疗性
肝腫瘤%超聲%高彊聚焦%結腸%化學栓塞%治療性
간종류%초성%고강취초%결장%화학전새%치료성
Liver neoplasms%Ultrasound,high-intensity focused,transrectal%Chemoembolization,therapeutic
目的 探讨高强度聚焦超声(HIFU)联合肝动脉化疗栓塞(TACE)治疗原发性肝癌(肝癌)的临床疗效.方法 106例肝癌患者分为两组,单纯TACE组50例(碘油栓塞或碘油栓塞联合5-氟尿嘧啶+多柔比星),联合组56例(HIFU+TACE).观察两组治疗后3个月的临床疗效和血清甲胎蛋白(AFP)的变化情况,观察两组患者的1、2、3年生存率.结果 单纯TACE组:CR0,PR20%,SD 52%;联合组:CR0,PR26.8%,SD 55.4%.AFP变化情况,单纯TACE组和联合组由治疗前的(472.3±104.2)μg/L和(491.8±125.2)μg/L,降为治疗后的(122.3±64.6)μg/L和(71.2±35.1)μg/L.1、2、3年生存率:联合组为82.3%、60.8%、39.2%;TACE组为68.0%、42.6%、21.0%.未发生皮肤烧伤、出血、胃肠道穿孔等并发症.结论 HIFU联合TACE是治疗肝癌的一种新的安全有效的治疗方法,可以明显延长肝癌患者的生存期,并且优于单纯TACE治疗.
目的 探討高彊度聚焦超聲(HIFU)聯閤肝動脈化療栓塞(TACE)治療原髮性肝癌(肝癌)的臨床療效.方法 106例肝癌患者分為兩組,單純TACE組50例(碘油栓塞或碘油栓塞聯閤5-氟尿嘧啶+多柔比星),聯閤組56例(HIFU+TACE).觀察兩組治療後3箇月的臨床療效和血清甲胎蛋白(AFP)的變化情況,觀察兩組患者的1、2、3年生存率.結果 單純TACE組:CR0,PR20%,SD 52%;聯閤組:CR0,PR26.8%,SD 55.4%.AFP變化情況,單純TACE組和聯閤組由治療前的(472.3±104.2)μg/L和(491.8±125.2)μg/L,降為治療後的(122.3±64.6)μg/L和(71.2±35.1)μg/L.1、2、3年生存率:聯閤組為82.3%、60.8%、39.2%;TACE組為68.0%、42.6%、21.0%.未髮生皮膚燒傷、齣血、胃腸道穿孔等併髮癥.結論 HIFU聯閤TACE是治療肝癌的一種新的安全有效的治療方法,可以明顯延長肝癌患者的生存期,併且優于單純TACE治療.
목적 탐토고강도취초초성(HIFU)연합간동맥화료전새(TACE)치료원발성간암(간암)적림상료효.방법 106례간암환자분위량조,단순TACE조50례(전유전새혹전유전새연합5-불뇨밀정+다유비성),연합조56례(HIFU+TACE).관찰량조치료후3개월적림상료효화혈청갑태단백(AFP)적변화정황,관찰량조환자적1、2、3년생존솔.결과 단순TACE조:CR0,PR20%,SD 52%;연합조:CR0,PR26.8%,SD 55.4%.AFP변화정황,단순TACE조화연합조유치료전적(472.3±104.2)μg/L화(491.8±125.2)μg/L,강위치료후적(122.3±64.6)μg/L화(71.2±35.1)μg/L.1、2、3년생존솔:연합조위82.3%、60.8%、39.2%;TACE조위68.0%、42.6%、21.0%.미발생피부소상、출혈、위장도천공등병발증.결론 HIFU연합TACE시치료간암적일충신적안전유효적치료방법,가이명현연장간암환자적생존기,병차우우단순TACE치료.
Objective To explore the clinical effect of high intensity focused ultrasound(HIFU)combined with transcatheter arterial chemoembolization(TACE)in the treatment of primary liver cancer.Methods A total of 106 patients with primary liver cancer were divided into two groups:50 cases were treated with TACE,and the other 56 were treated with combination of HIFU and TACE.The changes of AFP levels and the size of tumors after three months treatment were analyzed and compared with each other.The survival rates for one,two and three years were calculated with Kaplan-Meier method and compared between the two groups.Results In the two groups,AFP decreased significantly after treatment,but the combined group was superior to the other in AFP decrease.In the combined group,the 1-,2-and 3-year survival rates were higher than those in the TACE group with 82.3%,60.8%and 39.2% vs 68.0%,42.6%and 21.0%respectively(P＜0.01).No serious complications were seen,such as burn of skin,bleeding,gastrointestinal perforation. Conclusion The use of HIFU combined with TACE in the treatment of patients with primary liver cancers is feasible and safe.The combined group is superior to simple TACE for the management of primary liver cancers,and the former is more effective in decreasing AFP level and improving survival rates.
